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Abstract
Metformin is commonly used in diabetes mellitus type 2, with lactic
acidosis being a rare but potentially fatal complication of this
therapy. The management of metformin-associated lactic acidosis
(MALA) is controversial. Treatment may include supportive care,
activated charcoal, bicarbonate infusion, hemodialysis, or continuous
venovenous hemofiltration. In the previous issue of Critical Care,
Peters and colleagues systematically evaluated outcomes in MALA
patients admitted to their intensive care unit. The mortality rate of
patients who received dialysis was similar to that of patients who
were not dialyzed. However, it was the more acutely and
chronically ill patients who actually received dialysis. This suggests
that hemodialysis was beneficial in preventing a higher mortality
rate in those who required renal replacement therapy.
The literature on the management of metformin-associated
lactic acidosis (MALA) is sparse and consists of case reports
and case series. In the previous issue of Critical Care, Peters
and colleagues [1] presented a retrospective cohort study in
patients with MALA. This study represents an important step
forward in systematically evaluating outcomes in this rare but
serious condition.
Metformin is commonly used in type 2 diabetes mellitus and
accounts for approximately one third of all prescriptions for
oral hypoglycemic agents in the US [2]. The United Kingdom
Prospective Diabetes Study demonstrated impressive
reductions in diabetes-related endpoints and mortality in
overweight patients with type 2 diabetes who used this drug
[3]. A rare but extremely serious adverse effect of this
medication is lactic acidosis, which carries a staggering 50%
mortality rate [4].
Metformin is renally cleared and is known to accumulate in
patients with chronic kidney disease [4]. Current guidelines
stipulate that it be used with caution in estimated glomerular
filtration rates (eGFRs) of less than 60 mL/minute and not at
all in eGFRs of less than 30 mL/minute [5]. Identified risk
factors for MALA include acute kidney injury (AKI), hypoxe-
mia, sepsis, alcohol abuse, liver failure, myocardial infarction,
and shock [6]. Medications that interfere with renal hemo-
dynamic autoregulation (that is, angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, and non-
steroidal anti-inflammatory drugs) and volume depletion are
frequently implicated in generating the AKI leading to MALA
[4]. The incidence of MALA is quoted at 1 to 5 cases per
100,000 patient-years but may be as high as 30 cases per
100,000 patient-years [4].
The mainstay of MALA therapy is supportive care. Particular
attention should be paid to normalizing the acid-base im-
balance, eliminating offending medication, and treating
concomitant disease [4]. Activated charcoal may also have a
role, especially in cases of metformin overdose [6]. Intra-
venous sodium bicarbonate is commonly used to correct
blood pH. Renal replacement therapies, including conven-
tional hemodialysis and continuous venovenous hemo-
filtration, have been successfully employed in MALA [6-11].
These allow for both isovolemic correction of the metabolic
acidosis as well as removal of metformin and lactate [4].
Peters and colleagues [1] performed a 5-year retrospective
review of all patients admitted to their intensive care unit
presenting with MALA. They defined MALA as lactic acidosis
(lactate of greater than 5 mmol/L and bicarbonate of less than
22 mmol/L) occurring in a patient who was chronically taking
metformin or in the setting of a metformin overdose. No
patients actually had MALA as their admission diagnosis.
Most were admitted for management of shock or acute renal
failure. MALA was part of the clinical presentation in this
patient cohort rather than an admission diagnosis. MALA
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accounted for 0.84% of all admissions and demonstrated a
30% mortality rate. Eighty percent of these patients
developed acute renal failure and 62.5% required hemo-
dialysis. Only one patient with normal renal function was
dialyzed because of severe acidosis.
The definition of MALA in this study did not duly account for
people presenting primarily with tissue hypoperfusion as the
likely cause of their lactic acidosis. Although metformin may
interfere with lactate clearance in a shock state, it is not
thought to be the primary cause of the acidosis. Restoration
of hemodynamic stability rather than dialysis is the goal of
therapy in these cases. Most of the patients who died in this
study were admitted with shock, suggesting that hypo-
perfusion, rather than metformin, was the principal cause of
their lactic acidosis. However, MALA itself can present with
hypotension due to negative inotropic effects and increased
systemic vascular resistance with acidosis [4,6].
The mortality rate in MALA was not altered by hemodialysis.
This may be a reflection of the small size of this study. Upon
closer inspection of the data, those patients who were
dialyzed were more acutely ill as they had higher values on
the SAPS II (Simplified Acute Physiology Score II). Further-
more, those who were dialyzed trended toward having a
larger burden of comorbidity (Charlson index) and more
severe acidosis. These data strongly suggest that hemo-
dialysis may be of benefit in MALA. This is in keeping with the
available literature.
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